LMK-235

• CAT Number: I001606
• CAS Number: 1418033-25-6
• Molecular Formula: C15H22N2O4
• Molecular Weight: 294.41
• Purity: ≥95%
• Synonyms: N-((6-(hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide
• Target: Epigenetics
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: Store at -20°C
• IC50: 0.49 μM (A2780) and 0.32 μM (A2780 CisR) [1]
• IUPAC Name: N-[6-(hydroxyamino)-6-oxohexoxy]-3,5-dimethylbenzamide
• InChI: InChI=1S/C15H22N2O4/c1-11-8-12(2)10-13(9-11)15(19)17-21-7-5-3-4-6-14(18)16-20/h8-10,20H,3-7H2,1-2H3,(H,16,18)(H,17,19)
• InChIKey: VRYZCEONIWEUAV-UHFFFAOYSA-N
• SMILES: CC1=CC(=CC(=C1)C(=O)NOCCCCCC(=O)NO)C

LMK235(CAT: I001606) is a selective histone deacetylase (HDAC) inhibitor, specifically targeting human HDAC4 and HDAC5. It exhibits IC50 values of 0.49 μM in A2780 ovarian cancer cells and 0.32 μM in cisplatin-resistant A2780 CisR cells, highlighting its potency even in resistant cancer models. By inhibiting HDAC4/5, LMK235 modulates gene expression, inducing apoptosis and reducing cell proliferation. It is particularly significant in epigenetics and oncology research, where it aids in exploring therapeutic strategies for overcoming drug resistance and targeting HDAC-related pathways in cancer progression. Its specificity and efficacy make it a valuable tool for advancing HDAC-focused drug discovery.